| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705632 | Ophthalmology | 2016 | 7 Pages |
Abstract
The 5-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind as a result of RP. The Argus II is the first and only retinal implant to have market approval in the European Economic Area, the United States, and Canada.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Lyndon MD, Jessy D. PhD, Mark S. MD, PhD, Gislin PhD, James MD, Pierre-Olivier MD, José-Alain MD, Paulo E. MD, Farhad MD, PhD, Avinoam B. MD, Joel MD, Arturo MD, PhD, David PhD, Rand MD, Artur V. PhD, Eugene MD, Jacque L. MD, Dean MD, Robert J. MD, PhD,